SELPLG and neoplasm: A new immune checkpoint, P-selectin glycoprotein ligand-1 (PSGL-1, Selplg gene) has been shown to inhibit anti-tumor responses in pre-clinical models and may represent a new strategy to improve patient outcomes (42).